TG Therapeutics Inc
TGTX
Market Cap$5.34B
Close$
$-27.53
182.5% downside
Current Fair Value
182.5% downsideOvervalued by 182.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.34 Billion |
|---|---|
| Enterprise Value | $5.43 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $0.16 |
| Beta | 2.21 |
| Outstanding Shares | 155,788,222 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 224.13 |
|---|---|
| PEG | -232.03 |
| Price to Sales | 33.37 |
| Price to Book Ratio | 33.37 |
| Enterprise Value to Revenue | 20.49 |
| Enterprise Value to EBIT | -10745.47 |
| Enterprise Value to Net Income | -378 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 1.19 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About TG Therapeutics Inc
CEO: Michael Weiss